A randomized study comparing clinical efficacy and safety of thienamycin formamidine (MK0787)/renal dipeptidase inhibitor (MK0791) and cefazolin

1 October 1983

journal article
research article
Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy

Vol. 12 (4) , 387-391
https://doi.org/10.1093/jac/12.4.387

Abstract

Twenty-one hospitalized patients with infectious diseases were randomly assigned to receive either thienamycin formamidine/renal dipeptidase inhibitor or cefazolin. Infections treated included septicaemia, pneumonia, osteomyelitis, pyelonephritis, cellulitis and cutaneous abscesses. All eleven patients treated with thienamycin formamidine/renal dipeptidase inhibitor responded well to therapy. One of the ten patients treated with cefazolin developed a superinfection with Pseudomonas aeruginosa. Side effects detected were minor in both groups.

Keywords

This publication has 1 reference indexed in Scilit:

Comparative In Vitro Activities of N -Formimidoyl Thienamycin and Moxalactam Against Nonfermentative Aerobic Gram-Negative Rods
Antimicrobial Agents and Chemotherapy, 1982